NMOSD is a rare, antibody-mediated disorder often mistaken for MS. It is associated withantibodies against aquaporin-4 (AQP4). FDA-approved targeted therapies include:
- Eculizumab (Soliris®) – complement inhibition
- Inebilizumab (Uplizna®) – B-cell depletion
- Satralizumab (Enspryng®) – IL-6 receptor inhibition
These agents have dramatically reduced relapse rates and disability progression.